Google
Trusted Resources: News & Events
Latest announcements and gatherings
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States
New and life-saving therapy for patients with sickle cell disease (SCD) will soon be within reach. Vertex Pharmaceuticals (collaborating with CRISPR Therapeutics) and bluebird bio have each submitted biologic license applications to the U.S. Food and Drug Administration (FDA) for SCD gene therapy, and a rapid decision is expected. These therapies will join stem cell transplantation as the only curative options for adults with SCD.
A report from the Institute for Clinical and Economic Review predicts that the price of SCD gene therapy will be $2 million per patient (1). Given that more than 50 000 patients with SCD may be …
+myBinderRelated Content
-
Metabolic syndrome among adults living with sickle cell diseaseMetabolic syndrome (MetS) is a key risk ...
-
Camp Jumoke helping kids cope with sickle cell diseaseThere are unexpected things that happen ...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
-
10th Annual Sickle Cell Disease Therapeutics Conference – VirtualThe Annual Sickle Cell Disease Therapeut...
-
2019 WEPSCF Rockin’ the Red – 14th Annual FundraiserJoin us as we celebrate National Sickle ...
-
Kids with sickle cell disease aren’t receiving key vaccines, Michigan study findsA significant proportion of children w...
-
Non-invasive imaging of oxygen extraction fraction in adults with sickle cell anaemiaSickle cell anaemia is a monogenetic dis...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.